Marksans Pharma up 20% after inspection wind-up at Goa plant

Marksans Pharma today zoomed 20

per cent after the company said inspection by the UK health

regulator at its Goa plant has been completed without any

critical observations.

The stock skyrocketed 19.95 per cent to end at Rs 48.70

on BSE.

On NSE, it soared 20 per cent to close at Rs 48.60.

The company added Rs 332.36 crore to Rs 1,993.36 crore in

market valuation.

On the volume front, 92.82 lakh shares of the company

were traded on the BSE and over 4 crore shares changed hands

on the NSE during the day.

The plant located at Verna has had an inspection by the

UK Medicines and Healthcare products Regulatory Agency (MHRA)

from February 14-17, Marksans Pharma said in a BSE filing.

"The same has been completed without any critical

observations," it added.

The company, which makes formulations at the facility, is

awaiting further instruction from the agency in this regard,

Marksans Pharma said.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)